Vascular histone deacetylation by pharmacological HDAC inhibition
- Haloom Rafehi,
- Aneta Balcerczyk,
- Sebastian Lunke,
- Antony Kaspi,
- Mark Ziemann,
- Harikrishnan KN,
- Jun Okabe,
- Ishant Khurana,
- Jenny Ooi,
- Abdul Waheed Khan,
- Xiao-Jun Du,
- Lisa Chang,
- Izhak Haviv,
- Samuel T Keating,
- Tom C Karagiannis and
- Assam El-Osta1
- ↵* Corresponding author; email: assam.el-osta{at}bakeridi.edu.au
Abstract
HDAC inhibitors can regulate gene expression by post-translational modification of histone as well as non-histone proteins. Often studied at single loci, increased histone acetylation is the paradigmatic mechanism of action. However, little is known of the extent of genome-wide changes in cells stimulated by the hydroxamic acids, TSA and SAHA. In this article we map vascular chromatin modifications including histone H3 acetylation of lysine 9 and 14 (H3K9/14ac) using chromatin immunoprecipitation (ChIP) coupled with massive parallel sequencing (ChIP-seq). Since acetylation mediated gene expression is often associated with modification of other lysine residues we also examined H3K4me3 and H3K9me3 as well as changes in CpG methylation (CpG-seq). RNA sequencing indicates the differential expression of approximately 30% of genes, with almost equal numbers being up- and down-regulated. We observed broad deacetylation and gene expression changes conferred by TSA and SAHA mediated by the loss of EP300/CREBBP binding at multiple gene promoters. This study provides an important framework for HDAC inhibitor function in vascular biology and a comprehensive description of genome-wide deacetylation by pharmacological HDAC inhibition.
- Received October 26, 2013.
- Accepted April 9, 2014.
- Published by Cold Spring Harbor Laboratory Press
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.











